儿科患者使用诺基诺的安全性:药监数据库分析
Olga Butranova1, Yury Kustov1, Sergey Zyryanov1,2
1Department of General and Clinical Pharmacology, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN), Moscow, Russia.
The International journal of risk & safety in medicine
|November 18, 2025
概括
像勒沃素和西普罗素这样的诺基诺 (FQs) 越来越多地被处方给儿童. 这项研究发现,免疫和皮肤相关的不良药物反应 (ADR) 在接受FQs的儿科患者中最常见.
科学领域:
- 药物监督 药物监督 药物监督
- 儿科药理学 儿科药理学
- 传染性疾病 传染性疾病
背景情况:
- 抗生素耐药细菌的流行率不断上升,需要在儿科患者中增加诺 (FQs) 的使用.
- 国家药物监督数据库提供了对儿童FQs实际安全性的见解.
研究的目的:
- 分析与小儿科患者使用诺基诺相关的不良药物反应 (ADR) 的类型和结构.
主要方法:
- 俄罗斯国家药监数据库自发报告的回顾性分析 (2019年4月 - 2024年1月).
- 包括280个儿科自发报告 (SRs).
主要成果:
- 青少年 (62.9%) 是受影响最大的年龄组,平均年龄为12.1岁.
- 利沃素 (49.6%),西普罗素 (31.1%),和莫西素 (15%) 是主要的FQs.
- 最常见的不良反应涉及免疫障碍 (18.9%),胃肠道问题 (15.0%) 和皮肤反应 (14.7%),疹和腹是常见的.
结论:
- 列沃素,西普罗素和莫西素经常与儿科患者的不良反应有关.
- 过敏反应是观察到的ADR的主要类型.
- 仔细监测接受FQ的儿科患者在整个治疗过程和出院后至关重要.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Dosing: Infants and Children
235
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
235


